NCT04343976View on ClinicalTrials.gov

Pegylated Interferon Lambda Treatment for COVID-19

PHASE2TerminatedINTERVENTIONAL

Enrollment

14

Participants

Timeline

Start Date

June 22, 2020

Primary Completion Date

July 30, 2021

Study Completion Date

July 30, 2021

Conditions

COVID-19COVID

Interventions

DRUG

Pegylated interferon lambda

180 mcg subcutaneous injection of pegylated interferon lambda

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

Eiger BioPharmaceuticals

All Listed Sponsors

collaborator

Eiger BioPharmaceuticals

INDUSTRY

lead

Raymond Chung

OTHER

NCT04343976 - Pegylated Interferon Lambda Treatment for COVID-19 | Biotech Hunter | Biotech Hunter